Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Netball initiative promotes Movelat

Thornton & Ross has teamed up with sporting association England Netball to promote its Movelat pain relief range.

As part of the ongoing sponsorship deal, which launched this month, Movelat will appear in a number of national press adverts and “various communications” for England Netball’s Back To Netball initiative, Thornton & Ross said. There will also be “widespread PR support” to announce the partnership, it said.

Back To Netball is aimed at reintroducing women to the sport, and this can include the use of Movelat products to help people “get back to exercise by managing minor aches and sprains”, Thornton & Ross added.

The topical analgesic – which comes in cream and gel forms – contains a “unique dual action formula” that delivers a “clinically proven anti-inflammatory straight to the site of pain”, it claimed.

Movelat Relief Cream and Movelat Relief Gel both retail for £4.62.

To order, contact 01484 848200

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD007687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel